Do children benefit from mass screening for neuroblastoma?: Consensus Statement from the American Cancer Society Workshop on Neuroblastoma Screening
Gespeichert in:
| Veröffentlicht in: | The Lancet (British edition) 1991-02, Vol.337 (8737), p.344-346 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 346 |
|---|---|
| container_issue | 8737 |
| container_start_page | 344 |
| container_title | The Lancet (British edition) |
| container_volume | 337 |
| creator | Murphy, S.B Cohn, S.L Craft, A.W Woods, W.G Sawada, T Castleberry, R.P Levy, H.L Prorok, P.C Hammond, G.D |
| description | |
| doi_str_mv | 10.1016/0140-6736(91)90957-Q |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_80435817</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>014067369190957Q</els_id><sourcerecordid>80435817</sourcerecordid><originalsourceid>FETCH-LOGICAL-e176t-ce9eda08229d0a6d8e796d0c7aab958ca50d68227dbf61c03ff98fff72ea49013</originalsourceid><addsrcrecordid>eNpNkc1u1DAUha0K1A6lb9BKXiFYBK4niR2zAFVT_qQKVE0R3VmOfc0YEnuwHaS-Rx-4GTogVndxzv059yPklMFLBoy_AtZAxUXNn0v2QoJsRXV1QBasEU3VNuLmEVn8sxyRJzn_AICGQ3tIDhkXbNnUC3J3EanZ-MEmDLTHgM4X6lIc6ahzptkkxODDd-piogGnFPtB5xJH_fY1XcWQMeQp03XRBUcM-96yQXo-YvJGB7rSwWCi62g8llv6LaafeRO3NAb6-f-BdP132VPy2Okh48m-HpOv799drz5Wl18-fFqdX1bIBC-VQYlWQ7dcSgua2w6F5BaM0LqXbWd0C5bPqrC948xA7ZzsnHNiibqRwOpj8uxh7jbFXxPmokafDQ6DDhinrDpo6rZjYjae7Y1TP6JV2-RHnW7V_o2z_uZBx_na3x6TynPYObb1CU1RNnrFQO2wqR0TtWOiJFN_sKmr-h6Bl40Z</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>80435817</pqid></control><display><type>article</type><title>Do children benefit from mass screening for neuroblastoma?: Consensus Statement from the American Cancer Society Workshop on Neuroblastoma Screening</title><source>ScienceDirect</source><source>MEDLINE</source><source>Business Source Complete (EB_SDU_P3)</source><creator>Murphy, S.B ; Cohn, S.L ; Craft, A.W ; Woods, W.G ; Sawada, T ; Castleberry, R.P ; Levy, H.L ; Prorok, P.C ; Hammond, G.D</creator><creatorcontrib>Murphy, S.B ; Cohn, S.L ; Craft, A.W ; Woods, W.G ; Sawada, T ; Castleberry, R.P ; Levy, H.L ; Prorok, P.C ; Hammond, G.D</creatorcontrib><identifier>ISSN: 0140-6736</identifier><identifier>EISSN: 1474-547X</identifier><identifier>DOI: 10.1016/0140-6736(91)90957-Q</identifier><identifier>PMID: 1671243</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Age Factors ; Evaluation Studies as Topic ; Homovanillic Acid - urine ; Humans ; Infant ; Infant, Newborn ; Japan - epidemiology ; Mass Screening ; Neuroblastoma - epidemiology ; Neuroblastoma - mortality ; Neuroblastoma - prevention & control ; Neuroblastoma - urine ; Prognosis ; Survival Rate ; Vanilmandelic Acid - urine</subject><ispartof>The Lancet (British edition), 1991-02, Vol.337 (8737), p.344-346</ispartof><rights>1991</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/0140-6736(91)90957-Q$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1671243$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Murphy, S.B</creatorcontrib><creatorcontrib>Cohn, S.L</creatorcontrib><creatorcontrib>Craft, A.W</creatorcontrib><creatorcontrib>Woods, W.G</creatorcontrib><creatorcontrib>Sawada, T</creatorcontrib><creatorcontrib>Castleberry, R.P</creatorcontrib><creatorcontrib>Levy, H.L</creatorcontrib><creatorcontrib>Prorok, P.C</creatorcontrib><creatorcontrib>Hammond, G.D</creatorcontrib><title>Do children benefit from mass screening for neuroblastoma?: Consensus Statement from the American Cancer Society Workshop on Neuroblastoma Screening</title><title>The Lancet (British edition)</title><addtitle>Lancet</addtitle><subject>Age Factors</subject><subject>Evaluation Studies as Topic</subject><subject>Homovanillic Acid - urine</subject><subject>Humans</subject><subject>Infant</subject><subject>Infant, Newborn</subject><subject>Japan - epidemiology</subject><subject>Mass Screening</subject><subject>Neuroblastoma - epidemiology</subject><subject>Neuroblastoma - mortality</subject><subject>Neuroblastoma - prevention & control</subject><subject>Neuroblastoma - urine</subject><subject>Prognosis</subject><subject>Survival Rate</subject><subject>Vanilmandelic Acid - urine</subject><issn>0140-6736</issn><issn>1474-547X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1991</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkc1u1DAUha0K1A6lb9BKXiFYBK4niR2zAFVT_qQKVE0R3VmOfc0YEnuwHaS-Rx-4GTogVndxzv059yPklMFLBoy_AtZAxUXNn0v2QoJsRXV1QBasEU3VNuLmEVn8sxyRJzn_AICGQ3tIDhkXbNnUC3J3EanZ-MEmDLTHgM4X6lIc6ahzptkkxODDd-piogGnFPtB5xJH_fY1XcWQMeQp03XRBUcM-96yQXo-YvJGB7rSwWCi62g8llv6LaafeRO3NAb6-f-BdP132VPy2Okh48m-HpOv799drz5Wl18-fFqdX1bIBC-VQYlWQ7dcSgua2w6F5BaM0LqXbWd0C5bPqrC948xA7ZzsnHNiibqRwOpj8uxh7jbFXxPmokafDQ6DDhinrDpo6rZjYjae7Y1TP6JV2-RHnW7V_o2z_uZBx_na3x6TynPYObb1CU1RNnrFQO2wqR0TtWOiJFN_sKmr-h6Bl40Z</recordid><startdate>19910209</startdate><enddate>19910209</enddate><creator>Murphy, S.B</creator><creator>Cohn, S.L</creator><creator>Craft, A.W</creator><creator>Woods, W.G</creator><creator>Sawada, T</creator><creator>Castleberry, R.P</creator><creator>Levy, H.L</creator><creator>Prorok, P.C</creator><creator>Hammond, G.D</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>19910209</creationdate><title>Do children benefit from mass screening for neuroblastoma?: Consensus Statement from the American Cancer Society Workshop on Neuroblastoma Screening</title><author>Murphy, S.B ; Cohn, S.L ; Craft, A.W ; Woods, W.G ; Sawada, T ; Castleberry, R.P ; Levy, H.L ; Prorok, P.C ; Hammond, G.D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-e176t-ce9eda08229d0a6d8e796d0c7aab958ca50d68227dbf61c03ff98fff72ea49013</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1991</creationdate><topic>Age Factors</topic><topic>Evaluation Studies as Topic</topic><topic>Homovanillic Acid - urine</topic><topic>Humans</topic><topic>Infant</topic><topic>Infant, Newborn</topic><topic>Japan - epidemiology</topic><topic>Mass Screening</topic><topic>Neuroblastoma - epidemiology</topic><topic>Neuroblastoma - mortality</topic><topic>Neuroblastoma - prevention & control</topic><topic>Neuroblastoma - urine</topic><topic>Prognosis</topic><topic>Survival Rate</topic><topic>Vanilmandelic Acid - urine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Murphy, S.B</creatorcontrib><creatorcontrib>Cohn, S.L</creatorcontrib><creatorcontrib>Craft, A.W</creatorcontrib><creatorcontrib>Woods, W.G</creatorcontrib><creatorcontrib>Sawada, T</creatorcontrib><creatorcontrib>Castleberry, R.P</creatorcontrib><creatorcontrib>Levy, H.L</creatorcontrib><creatorcontrib>Prorok, P.C</creatorcontrib><creatorcontrib>Hammond, G.D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>The Lancet (British edition)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Murphy, S.B</au><au>Cohn, S.L</au><au>Craft, A.W</au><au>Woods, W.G</au><au>Sawada, T</au><au>Castleberry, R.P</au><au>Levy, H.L</au><au>Prorok, P.C</au><au>Hammond, G.D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Do children benefit from mass screening for neuroblastoma?: Consensus Statement from the American Cancer Society Workshop on Neuroblastoma Screening</atitle><jtitle>The Lancet (British edition)</jtitle><addtitle>Lancet</addtitle><date>1991-02-09</date><risdate>1991</risdate><volume>337</volume><issue>8737</issue><spage>344</spage><epage>346</epage><pages>344-346</pages><issn>0140-6736</issn><eissn>1474-547X</eissn><cop>England</cop><pub>Elsevier Ltd</pub><pmid>1671243</pmid><doi>10.1016/0140-6736(91)90957-Q</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0140-6736 |
| ispartof | The Lancet (British edition), 1991-02, Vol.337 (8737), p.344-346 |
| issn | 0140-6736 1474-547X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_80435817 |
| source | ScienceDirect; MEDLINE; Business Source Complete (EB_SDU_P3) |
| subjects | Age Factors Evaluation Studies as Topic Homovanillic Acid - urine Humans Infant Infant, Newborn Japan - epidemiology Mass Screening Neuroblastoma - epidemiology Neuroblastoma - mortality Neuroblastoma - prevention & control Neuroblastoma - urine Prognosis Survival Rate Vanilmandelic Acid - urine |
| title | Do children benefit from mass screening for neuroblastoma?: Consensus Statement from the American Cancer Society Workshop on Neuroblastoma Screening |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T14%3A08%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Do%20children%20benefit%20from%20mass%20screening%20for%20neuroblastoma?:%20Consensus%20Statement%20from%20the%20American%20Cancer%20Society%20Workshop%20on%20Neuroblastoma%20Screening&rft.jtitle=The%20Lancet%20(British%20edition)&rft.au=Murphy,%20S.B&rft.date=1991-02-09&rft.volume=337&rft.issue=8737&rft.spage=344&rft.epage=346&rft.pages=344-346&rft.issn=0140-6736&rft.eissn=1474-547X&rft_id=info:doi/10.1016/0140-6736(91)90957-Q&rft_dat=%3Cproquest_pubme%3E80435817%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=80435817&rft_id=info:pmid/1671243&rft_els_id=014067369190957Q&rfr_iscdi=true |